2024
Asthma control in the United States: relationships between short-acting β2-agonist and systemic corticosteroid use
Chupp G, Murphy K, Gandhi H, Gilbert I, Bleecker E. Asthma control in the United States: relationships between short-acting β2-agonist and systemic corticosteroid use. Annals Of Allergy Asthma & Immunology 2024 PMID: 38740134, DOI: 10.1016/j.anai.2024.05.003.Peer-Reviewed Original ResearchMild to moderate diseaseSystemic corticosteroidsMild-to-moderateSevere asthmaUncontrolled asthmaSystemic corticosteroid exposureSystemic corticosteroid useAsthma control assessmentCorticosteroid useExacerbation historyRetrospective analysisSABA useUS patientsPrescription fillsPatientsLongitudinal accessAsthma controlDisease severityAsthmaDiseaseExacerbationPearson correlation coefficientHigh symptom burdenPatient severitySymptom burden
2023
Mepolizumab Reduces Systemic Corticosteroid Use in Chronic Rhinosinusitis With Nasal Polyps
Chupp G, Alobid I, Lugogo N, Kariyawasam H, Bourdin A, Chaker A, Smith S, Sousa A, Mayer B, Chan R, Matucci A. Mepolizumab Reduces Systemic Corticosteroid Use in Chronic Rhinosinusitis With Nasal Polyps. The Journal Of Allergy And Clinical Immunology In Practice 2023, 11: 3504-3512.e2. PMID: 37586475, DOI: 10.1016/j.jaip.2023.08.015.Peer-Reviewed Original ResearchConceptsSevere chronic rhinosinusitisOral corticosteroid doseSystemic corticosteroidsNasal polypsChronic rhinosinusitisCorticosteroid doseSinus surgerySCS useTreatment responseLong-term adverse effectsPlacebo treatment responsePrior sinus surgeryPatient baseline characteristicsBlood eosinophil countsSystemic corticosteroid useMepolizumab efficacyCorticosteroid useWeek 52Baseline characteristicsEosinophil countClinical benefitCare treatmentMepolizumabRhinosinusitisPlacebo